With interest we read the article by Incecik *et al.*\[[@ref1]\] about a 10-year-old boy, born to consanguineous parents, with late-onset Leigh syndrome due to the variant c.1268C\>T in the *NDUFV1* gene who initially presented with gait ataxia. We have the following comments and concerns.

Leigh syndrome is characterized by symmetric T2-hyperintensities of the basal ganglia, the brainstem, or the cerebellum.\[[@ref2]\] However, Figure 1 of the case report shows asymmetric hyperintensity of the caput of the caudate nucleus.\[[@ref1]\] Did hyperintensities of the caudate nucleus become bilaterally symmetric during follow-up?

The patient presented with marked cerebellar signs (horizontal nystagmus, ataxic gait, dysarthria, dysmetria, dysdiadochokinesia, and bilateral intention tremor).\[[@ref1]\] Since Figure 1 does show the cerebellum properly, it would be interesting to know if there was cerebellar atrophy or other cerebellar lesions on imaging? Was there involvement of the cerebellar cortex or the cerebellar nuclei?

It would be interesting to know why the *NDUFV1* gene was tested. Did the authors apply exome sequencing or did they apply a targeted, single-gene approach? Since the parents were obviously asymptomatic, the trait of inheritance is most likely autosomal recessive. Did any of the two parents or both carry the mutation in the *NDUFV1* gene of the index case?

Mutations in *NDUFV1* are usually associated with deficiency of complex I of the respiratory chain. Were biochemical investigations of the muscle homogenate or another tissue carried out and was complex I deficiency detected?

Since Leigh syndrome is a progressive disease in the majority of the cases, it would be interesting to know for how long the patient was followed up and if there was progression of the clinical, radiologic, or spectroscopic findings. Did the patient develop epilepsy, spasticity, insomnia, tremor, dystonia, personality change, myopathy, and visual impairment, as has been previously reported in association with *NDUFV1* mutations \[[Table 1](#T1){ref-type="table"}\].

###### 

Phenotypic manifestations of *NDUFV1* mutations

  **Organ**                               **Manifestation**                      **References**
  --------------------------------------- -------------------------------------- -----------------------------------
  Cerebrum                                Cystic leucoencephalopathy             Whadwa *et al*. (2018)\[[@ref5]\]
  Regression of motor milestones          Zafeiriou *et al*. (2008)\[[@ref6]\]   
  Spastic diplegia                        Zafeiriou *et al*. (2008)              
  Infantile bilateral striatal necrosis   Lal *et al*. (2013)\[[@ref7]\]         
  Mental retardation                      Bénit *et al*.\[[@ref3]\]              
  Apnea                                   Bénit *et al*.\[[@ref3]\]              
  Lethargy                                Bénit *et al*.\[[@ref3]\]              
  Ataxia                                  Incecik *et al*.\[[@ref1]\]            
  Spasticity                              Baertling *et al*. (2018)\[[@ref8]\]   
  Leucodystrophy                          Schuelke *et al*. (1999)\[[@ref9]\]    
  Myoclonic epilepsy                      Schuelke *et al*. (1999)               
  Depression                              Baertling *et al*. (2018)              
  Insomnia                                Baertling *et al*. (2018)              
  Personality change                      Baertling *et al*. (2018)              
  Aphonia                                 Baertling *et al*. (2018)              
  Cerebellar atrophy                      Baertling *et al*. (2018)              
  Tremor                                  Baertling *et al*. (2018)              
  Dystonia                                Laugel *et al*.\[[@ref4]\]             
  Muscle                                  Ophthalmoplegia                        Laugel *et al*.\[[@ref4]\]
  Ptosis                                  Bénit *et al*.\[[@ref3]\]              
  Limb muscle weakness                    Baertling *et al*. (2018)              
  Lactic acidosis                         Baertling *et al*. (2018)              
  Eyes                                    Leber's optic neuropathy               Baertling *et al*. (2018)

Nothing is reported about any therapeutic intervention.\[[@ref1]\] Did the patient receive coenzyme-Q, riboflavin,\[[@ref3]\] a ketogenic diet,\[[@ref4]\] or L-carnitine and was any of these measures effective in the index case? Which was the long-term outcome of the patient?

In conclusion, this interesting case could be more meaningful if clinical and genetic data of the consanguineous parents would have been provided, if biochemical investigations would have been carried out, if imaging data of the cerebellum would have been provided, and if applied therapeutic interventions would have been discussed.
